What this study is
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.
What's being tested
- Amplification of Positivity - Cannabis Use (AMP-C)
Intervention · BEHAVIORAL
AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
Study details
- Official title
- AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use
- Sponsor
- Massachusetts General Hospital
- Conditions
- Depression - Major Depressive Disorder · Cannabis Use Disorder · Mental Disorder
- Enrolling
- 80 people
- Starts
- 2026-02-23
- Est. completion
- 2029-06-29
- Design
- Single-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Aged ≥ 18 years
- Resides in the United States
- Able to read and understand English and willing to provide informed consent/comply with the study protocol
- Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
- Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
- Current elevated anhedonia, as indicated by the PHQ-9
- Interest in receiving treatment for their cannabis use and depression
- Meet criteria for current MDD and CUD per the DSM-5
You can't join if
- History of a psychotic disorder or bipolar disorder type I/II
- Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
- Current psychotherapy engagement
- Changes in psychotropic medication within six weeks of the start of study
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMassachusetts General Hospital
Boston, Massachusetts, United States
- Shirley Wu, BS · Contact617-724-3532swu24@mgh.harvard.edu
- Amanda C Collins, PhD · Principal investigator
Recruiting
Study team
Sponsor
Massachusetts General Hospital
Study ID 2025p000583
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.